Delcath Systems, Inc. (DCTH) Stock: Price, Forecast & Analyst Target
Delcath Systems, Inc. (DCTH) — MoonshotScore 94/100 (Exceptional band), calculated Nov 18, 2026. Price $19.24 (-2.34%), as of the Nov 19, 2026 trading session; market cap $669M.
Educational signal · not a buy or sell recommendation · How to read this
Delcath Systems, Inc. · DCTH · NASDAQ
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Their lead product, HEPZATO KIT, delivers high-dose chemotherapy to the liver while controlling systemic exposure.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Delcath Systems (DCTH)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $21M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 6 of the last 8 reports
- Altman Z 23.20 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $19.24 | |
| Change on the day | -2.34% | |
| 52-week range | $8.12 – $22.51 | |
| Market capitalisation | $669M | — |
| Price / earnings (trailing) | 108.82 | |
| Shares traded on the day | 459.6K |
Price & events
Other perspectives
Council score for Delcath Systems (DCTH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Delcath Systems (DCTH), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Delcath Systems, Inc. (DCTH) is listed on NASDAQ. It employs 156 people and is led by Gerard J. Michel. In Q3 FY2025 it reported revenue of $21M and net income of $830,000. The market values it at $669M.
What do the latest results show for Delcath Systems (DCTH)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $21M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $21M | $830,000 | $0.02 (diluted) |
| Q4 FY2025 | $21M | -$2M | -$0.05 (diluted) |
| Q1 FY2026 | $25M | -$1M | -$0.03 (diluted) |
| Q2 FY2026 | $29M | $3M | $0.07 (diluted) |
What are the financial strengths and risks for Delcath Systems (DCTH)?
Short answer · as of
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 23.20 · Piotroski F 7. Trailing ratios: ROE 5.6% · ROA 4.5% · current ratio 10.87 · earnings yield 0.9% · free-cash-flow yield 2.9%.
What should you watch next at Delcath Systems (DCTH)?
Short answer · as of
Current published price targets run low $25.00 · high $32.00 · consensus $28.50 · median $28.50 against a quoted price of $19.24 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Nov 4, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Delcath Systems compare with its peers?
Short answer
Delcath Systems's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| Delcath Systems (DCTH) — this page | $19.24 | $669M | 94 |
| $81.26 Nov 19, 2026 | $1.04B | 94 5-pillar Nov 18, 2026 | |
| $12.88 Nov 18, 2026 | $741M | 92 5-pillar Nov 18, 2026 | |
| $26.42 Nov 18, 2026 | $592M | 90 5-pillar Nov 18, 2026 | |
| $8.98 Nov 18, 2026 | $361M | 87 5-pillar Nov 18, 2026 | |
| $10.62 Nov 18, 2026 | $727M | 79 5-pillar Nov 18, 2026 | |
| $13.86 Nov 18, 2026 | $1.08B | 68 5-pillar Nov 18, 2026 | |
| $18.15 Nov 18, 2026 | $771M | 62 5-pillar Nov 18, 2026 | |
| $23.75 Nov 19, 2026 | $1.07B | 39 5-pillar Nov 18, 2026 | |
| $32.51 Nov 19, 2026 | $849M | 37 5-pillar Nov 18, 2026 | |
| $9.52 Nov 18, 2026 | $396M | 35 5-pillar Nov 18, 2026 | |
| $10.62 Nov 19, 2026 | $590M | 34 5-pillar Nov 18, 2026 | |
| $18.54 Nov 18, 2026 | $905M | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $25.00 – $32.00
- Consensus target
- $28.50
- Median target
- $28.50
Consensus record · Captured .
Measured against a quoted price of $19.24 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 13, 2026
- Transactions
- 3
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DCTH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DCTH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Delcath Systems (DCTH)?
- Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
- Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
- BTIG Reiterates Buy on Delcath Systems, Maintains $25 Price Target
- Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet
What Investors Ask About Delcath Systems (DCTH)
These answers are editorial: 1 of these 9 answers is drawn from the DCTH research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for DCTH?
DCTH carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers.
Is DCTH a good stock to buy?
Stock Expert AI does not rate DCTH buy, sell or hold. Delcath Systems, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the DCTH stock price today?
The last price recorded for Delcath Systems, Inc. (DCTH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DCTH price target?
The analyst consensus price target for Delcath Systems, Inc. (DCTH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
How does Delcath Systems, Inc. navigate regulatory approval processes for its specialized therapies?
Delcath Systems, Inc. navigates regulatory approval processes through distinct pathways for its key markets. In Europe, the CHEMOSAT Hepatic Delivery System has obtained CE Mark approval, allowing its commercialization as a medical device for treating a range of liver cancers.
What are the key factors to evaluate for DCTH?
Delcath Systems, Inc. (DCTH) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does DCTH data refresh on this page?
DCTH's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven DCTH's recent stock price performance?
Delcath Systems, Inc. (DCTH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary HEPZATO KIT/CHEMOSAT system offers a unique regional chemotherapy delivery method. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DCTH overvalued or undervalued right now?
The trailing P/E of Delcath Systems, Inc. (DCTH) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold DCTH
Funds in our ETF coverage that list DCTH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Simplify Propel Opportunities ETF (SURI) | 2.98% |